AbCellera reports Q2 net loss $34.7M, revenue up 134% YoY; starts Phase 1 for VMS drug ABCL635

AbCellera Biologics Inc.

2025-Q2 EPS reported -$0.27 vs consensus -$0.17 ▼ miss (-59.5%)

Revenue $17.1M vs $7.3M YoY (134% increase); net loss $34.7M ($0.12 loss per share) vs $36.9M ($0.13) prior year.
First participants dosed in Phase 1 trial of ABCL635 for vasomotor symptoms; initial data expected mid-2026.
Cumulative partner-initiated program starts reached 102 (+9 YoY); molecules in clinic 18 (+4 YoY).
Net loss per share $(0.12) versus $(0.13); R&D expenses $39.2M, G&A $19.0M.
Total liquidity of $753M including $580M cash/securities and $173M in non-dilutive government funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.